Capivasertib (Truqap)

Key Messages

• Note: Due an administrative error, the patient input submission from Breast Cancer Canada was mistakenly omitted from the review and is not reflected in the review reports or the recommendation document. CDA-AMC appreciates the effort required to compile patient group input. The input from Breast Cancer Canada has been included in the summary document to ensure that their contributions to the reimbursement review process are reflected in final documentation and their valuable input is available to our health system partners and other interested parties. 
  
  
• CADTH recommends that Truqap in combination with fulvestrant should be reimbursed by public drug plans for the treatment of adults with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy, if certain conditions are met.
• Truqap plus fulvestrant should only be covered to treat adults who have HR-positive, HER2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations and are in relatively good health. Truqap plus fulvestrant should not be covered in patients who have progressed on prior therapy with fulvestrant, received more than 2 lines of hormone therapy, or received more than 1 line of chemotherapy in the metastatic setting.
• Truqap plus fulvestrant should only be reimbursed if prescribed and administered by health professionals experienced in the management of breast cancer at treatment centres with adequate resources to manage side effects, and if the price of Truqap is reduced. Lastly, it must be feasible to test patients for PIK3CA, AKT1, or PTEN